You Make the Call: How would you treat this transplant-ineligible patient with Ph+ ALL?
This month, Geoffrey Uy, MD, discusses treatment options for a transplant-ineligible patient with Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL).
And don't forget to check...
You Make the Call: Is JAK2 positivity clinically significant in this 28-year-old patient with Budd-Chiari...
This month, Peter Emanuel, MD, discusses the clinical significance of JAK2 positivity in a patient with Budd-Chiari syndrome.
And don't forget to check out next...
Corticosteroid-Dependent or Corticosteroid-Unresponsive Primary ITP
This month, Waleed Ghanima, MD, PhD, Terry Gernsheimer, MD, and David J. Kuter, MD, DPhil, review treatment options for adult patients with primary immune...
You Make the Call: How would you manage this patient with T-cell large granular...
This month, Richard Furman, MD, discusses management of a patient with T-cell large granular lymphocytic leukemia.
And don't forget to check out next month's clinical...
Afibrinogenemia: A Rare, Often Overlooked Bleeding Disorder
Afibrinogenemia is a very rare, inherited blood disorder in which the blood does not clot normally because of a mutation that leads to the...
Demystifying the Lab: Cytogenetics
Clinical applications abound for the study of structural abnormalties in chromosomes.
The first chromosomal abnormality discovered in cancer using cytogenetics is likely still one of...
You Make the Call: How would you approach diathesis in a 65-year-old woman with...
This month, Barbara Konkle, MD, discusses a bleeding diathesis in a 65-year-old woman with newly diagnosed breast cancer.
And don't forget to check out next...
Venetoclax-Based Treatments for Chronic Lymphocytic Leukemia
William G. Wierda, MD, PhD, and Francesco Paolo Tambaro, MD, PhD, review the role of venetoclax and other targeted therapies in the treatment of...
You Make the Call: How would you treat this 38-year-old patient with sickle cell trait...
This month, Maureen Achebe, MD, MPH, discusses treatment for a patient with sickle cell trait and end-stage renal disease.
And don't forget to check out...
You Make the Call: Should a mostly asymptomatic patient with amyloidosis receive systemic therapy?
This month Morie A. Gertz, MD, discusses whether a mostly asymptomatic patient with amyloidosis should receive systemic therapy.
And don't forget to check out next...
Current Issue
October 2021, Volume 7, Issue 12
This issue tells the long story of drug shortages, demystifies transfusion services, and more.